BR112016020333A2 - compostos orgânicos de monobactam para o tratamento de infecções bacterianas - Google Patents

compostos orgânicos de monobactam para o tratamento de infecções bacterianas

Info

Publication number
BR112016020333A2
BR112016020333A2 BR112016020333A BR112016020333A BR112016020333A2 BR 112016020333 A2 BR112016020333 A2 BR 112016020333A2 BR 112016020333 A BR112016020333 A BR 112016020333A BR 112016020333 A BR112016020333 A BR 112016020333A BR 112016020333 A2 BR112016020333 A2 BR 112016020333A2
Authority
BR
Brazil
Prior art keywords
treatment
organic compounds
bacterial infections
monobactam
monobactam organic
Prior art date
Application number
BR112016020333A
Other languages
English (en)
Other versions
BR112016020333B1 (pt
Inventor
Casarez Anthony
Yifru Aregahegn
Reck Folkert
Mcenroe Glenn
Ernst Moser Heinz
Tjandra Meiliana
Lindvall Mika
Zhu Qingming
Lowell Simmons Robert
Singh Aulakh Virender
Lin Xiadong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016020333A2 publication Critical patent/BR112016020333A2/pt
Publication of BR112016020333B1 publication Critical patent/BR112016020333B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

esta invenção pertence geralmente aos compostos antibacterianos de fórmula i, (i) como também descrito aqui, e sais farmaceuticamente aceitáveis e formulações dos mesmos. em certos aspectos, a invenção pretence aos métodos de usar tais compostos para tratar infecções tais como aquelas causadas por bactérias gram-negativas.
BR112016020333-0A 2014-03-24 2015-03-23 Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas BR112016020333B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US61/969,735 2014-03-24
US201462088304P 2014-12-05 2014-12-05
US62/088,304 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
BR112016020333A2 true BR112016020333A2 (pt) 2017-10-24
BR112016020333B1 BR112016020333B1 (pt) 2022-08-09

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020333-0A BR112016020333B1 (pt) 2014-03-24 2015-03-23 Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas

Country Status (36)

Country Link
US (4) US9174978B2 (pt)
EP (2) EP3122745B1 (pt)
JP (1) JP6153674B2 (pt)
KR (1) KR101733441B1 (pt)
CN (1) CN106164072B (pt)
AP (1) AP2016009374A0 (pt)
AU (1) AU2015236369B2 (pt)
BR (1) BR112016020333B1 (pt)
CA (1) CA2939254C (pt)
CL (1) CL2016002285A1 (pt)
CU (1) CU24441B1 (pt)
CY (1) CY1121701T1 (pt)
DK (2) DK3122745T3 (pt)
EA (1) EA030850B1 (pt)
EC (1) ECSP16073620A (pt)
ES (2) ES2719136T3 (pt)
GT (1) GT201600183A (pt)
HR (1) HRP20190501T1 (pt)
HU (1) HUE042134T2 (pt)
IL (1) IL247259B (pt)
LT (1) LT3122745T (pt)
MA (1) MA39777B1 (pt)
MX (1) MX2016011822A (pt)
MY (1) MY179292A (pt)
PE (1) PE20161371A1 (pt)
PH (1) PH12016501577A1 (pt)
PL (1) PL3122745T3 (pt)
PT (1) PT3122745T (pt)
RS (1) RS58509B1 (pt)
SG (1) SG11201606711UA (pt)
SI (1) SI3122745T1 (pt)
SV (1) SV2016005274A (pt)
TW (1) TWI714525B (pt)
UA (1) UA121383C2 (pt)
WO (1) WO2015148379A1 (pt)
ZA (1) ZA201605565B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10919887B2 (en) * 2015-09-23 2021-02-16 Novartis Ag Salts and solid forms of a monobactam antibiotic
US20180282331A1 (en) 2015-11-09 2018-10-04 Wockhardt Limited 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS
RU2746129C2 (ru) 2015-12-15 2021-04-07 Мерк Шарп И Доум Корп. Биарильные монобактамные соединения и способы их применения для лечения бактериальных инфекций
MX2018010878A (es) 2016-03-07 2018-11-09 Merck Sharp & Dohme Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
US11174260B2 (en) 2017-03-20 2021-11-16 The Broad Institute, Inc. Compounds and methods for the treatment of parasitic diseases
ES2912656T3 (es) * 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EA202090604A1 (ru) 2017-10-02 2020-10-15 Мерк Шарп энд Доум Корп. Хроманмонобактамовые соединения для лечения бактериальных инфекций
MX2020004071A (es) * 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
CN111511737B (zh) 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3882246A4 (en) 2018-11-13 2021-12-29 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
JP7179185B2 (ja) * 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β－ラクタム化合物の使用
EP4046998B1 (en) * 2019-11-22 2024-02-28 Suzhou Erye Pharmaceutical Co., Ltd. Sulfonylurea ring substituted monocyclic beta-lactam antibiotics
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
US20230022708A1 (en) 2019-12-19 2023-01-26 Medshine Discovery Inc. Application of compound in drug preparation
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2023091438A1 (en) 2021-11-18 2023-05-25 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
CN115304594B (zh) 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd １−スルホ−２−アゼチジノン誘導体およびその製造法
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
KR900005112B1 (ko) 1982-05-31 1990-07-19 반유세이야꾸 가부시끼가이샤 2-옥소-1-아제티딘술폰산 유도체의 제조방법
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ATE376837T1 (de) 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2525717A1 (en) 2003-05-23 2004-12-09 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
CA2736953C (en) 2008-10-31 2017-07-11 Shionogi & Co., Ltd. Cephalosporins having catechol group
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
SG190007A1 (en) * 2010-11-29 2013-06-28 Pfizer Monobactams
MY157301A (en) 2011-08-25 2016-05-31 Merck Sharp & Dohme Pyrimidine pde10 inhibitors
RU2569307C1 (ru) 2011-09-13 2015-11-20 Вокхардт Лимитед Азотсодержащие соединения и их применение
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
CN104334555A (zh) 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 异噁唑β-内酰胺酶抑制剂
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Also Published As

Publication number Publication date
EA201691766A1 (ru) 2016-12-30
US20190231752A1 (en) 2019-08-01
JP2017510580A (ja) 2017-04-13
PL3122745T3 (pl) 2019-08-30
EP3122745A1 (en) 2017-02-01
AU2015236369A1 (en) 2016-09-01
SG11201606711UA (en) 2016-10-28
ES2862203T3 (es) 2021-10-07
JP6153674B2 (ja) 2017-06-28
US20160051523A1 (en) 2016-02-25
WO2015148379A1 (en) 2015-10-01
CU20160131A7 (es) 2017-02-02
SV2016005274A (es) 2018-06-12
MA39777A (fr) 2017-02-01
CN106164072A (zh) 2016-11-23
ECSP16073620A (es) 2018-12-31
US9174978B2 (en) 2015-11-03
NZ723114A (en) 2020-12-18
EP3511328B1 (en) 2021-03-03
CA2939254A1 (en) 2015-10-01
RS58509B1 (sr) 2019-04-30
BR112016020333B1 (pt) 2022-08-09
TW201540712A (zh) 2015-11-01
IL247259A0 (en) 2016-09-29
CN106164072B (zh) 2019-10-01
MY179292A (en) 2020-11-03
US20200276169A1 (en) 2020-09-03
GT201600183A (es) 2018-12-18
DK3122745T3 (en) 2019-04-08
EA030850B1 (ru) 2018-10-31
HUE042134T2 (hu) 2019-06-28
CU24441B1 (es) 2019-09-04
DK3511328T3 (da) 2021-03-22
US10369138B2 (en) 2019-08-06
CA2939254C (en) 2023-02-14
US20150266867A1 (en) 2015-09-24
CY1121701T1 (el) 2020-07-31
EP3122745B1 (en) 2019-02-27
CL2016002285A1 (es) 2016-12-30
MA39777B1 (fr) 2019-03-29
EP3511328A1 (en) 2019-07-17
PE20161371A1 (es) 2016-12-21
ZA201605565B (en) 2017-09-27
AP2016009374A0 (en) 2016-08-31
HRP20190501T1 (hr) 2019-05-03
ES2719136T3 (es) 2019-07-08
MX2016011822A (es) 2016-12-02
KR101733441B1 (ko) 2017-05-10
IL247259B (en) 2020-02-27
PT3122745T (pt) 2019-04-30
TWI714525B (zh) 2021-01-01
AU2015236369B2 (en) 2017-02-16
LT3122745T (lt) 2019-04-10
PH12016501577A1 (en) 2016-10-03
SI3122745T1 (sl) 2019-05-31
KR20160110541A (ko) 2016-09-21
UA121383C2 (uk) 2020-05-25

Similar Documents

Publication Publication Date Title
BR112016020333A2 (pt) compostos orgânicos de monobactam para o tratamento de infecções bacterianas
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
CO2019002624A2 (es) Compuestos antibióticos
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2017009094A (es) Derivado de polimixina y usos del mismo.
PH12016501988A1 (en) Antibacterial compounds
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
ZA202002093B (en) Antibacterial compounds
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
BR112018011670A2 (pt) compostos antibacterianos
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
CO2019001995A2 (es) Inhibidores de beta-lactamasa
BR112017022796A2 (pt) composições antibacterianas e métodos
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية
CR20160412A (es) Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas
BR112015020342A2 (pt) selamectina para tratamento de infestações de piolhos do mar

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2015, OBSERVADAS AS CONDICOES LEGAIS